RxDoctor Payments Data

Genkai Huang

Family Medicine · Amarillo, TXNPI 1053949362

Payments from drug & device makers

$5,586in general payments, 2019–2025

Across 228 payments — averaging $24.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$558
  • AbbVie$552
  • Phathom Pharmaceuticals, Inc.$543
  • Abbott$532
  • GSK$511
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,586100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,586 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$240,149
Medicare patients
263
Services billed
4,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide292$364,117
FarxigaDapagliflozin Propanediol112$147,054
OzempicSemaglutide96$135,562
JardianceEmpagliflozin81$108,542
Trelegy ElliptaFluticasone/Umeclidin/Vilanter116$86,012
EliquisApixaban52$56,145
Nurtec OdtRimegepant Sulfate23$38,617
WegovySemaglutide19$32,039
XareltoRivaroxaban25$28,828
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$26,446
AuvelityDextromethorphan Hbr/Bupropion11$25,309
TrulicityDulaglutide12$19,921
Tresiba Flextouch U-200Insulin Degludec18$18,279
Repatha SureclickEvolocumab24$14,438
QuliptaAtogepant11$12,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$213$384,038304 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,132$173,500150 claims
Novo NordiskOzempic, Wegovy$558$167,601115 claims
Boehringer IngelheimJardiance$23$108,54281 claims
PfizerEliquis, Nurtec Odt$229$94,76275 claims
GSKTrelegy Ellipta$511$86,012116 claims
Johnson & JohnsonXarelto$34$28,82825 claims
Axsome Therapeutics, Inc.Auvelity$284$25,30911 claims
AbbVieQulipta$552$12,08711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →